ScreenerHero

DTILPrecision BioSciences, Inc.

NAS · US · Healthcare · Biotechnology · precisionbiosciences.com
8.850USD+4.12%Mkt Cap: 244.27M $P/E: —

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARC…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap244.27M $
Enterprise Value181.24M $
Revenue (TTM)45.05M $
Gross Profit45.05M $
Net Income (TTM)-45.72M $
Revenue/Share2.213 USD
Last Price8.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees67
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS74019P1084
Valuation
P/E (Trailing)—
P/E (Forward)-4.64
PEG—
EV/EBITDA-5.16
EV/Revenue4.02
P/S5.34
P/B5.09
EPS (TTM)-1.35
EPS (Forward)-1.88
52W Range
3.53087% of range9.620
52W High9.620 USD
52W Low3.530 USD
Profitability
Gross Margin100.00%
Oper. Margin-80.78%
EBITDA Margin-78.01%
Profit Margin-133.45%
ROE-49.57%
ROA-29.61%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.84M $
CapEx (TTM)700.00K $
FCF Margin-36.07%
FCF Yield-6.65%
Net Debt-59.45M $
Net Debt/EBITDA1.69
Balance Sheet
Debt/Equity0.31
Current Ratio12.82
Quick Ratio12.26
Book Value/Sh1.713 USD
Cash/Share3.172 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateFeb 14, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)29.40 USD
Upside (mean)+232.2%
Target Range18.00 USD – 60.00 USD
$18.00+232.2% to mean$60.00
# Analysts5
Ownership
Shares Out.27.60M
Float25.96M
Insiders6.19%
Institutions68.65%
Short Interest
Short Ratio6.3d
Short % Float11.17%
Short % Out.10.89%
Shares Short2.88M
Short (prev mo.)2.30M
Technical
SMA 507.539 (+17.4%)
SMA 2006.056 (+46.1%)
Beta1.23
S&P 52W Chg18.16%
Avg Vol (30d)324.81K
Avg Vol (10d)284.63K
Technical Indicators
RSI (14)71.6
MACD0.1490
MACD Signal0.0034
MACD Hist.+0.1456
BB Upper8.360 USD
BB Middle7.426 USD
BB Lower6.491 USD
BB Width25.18%
ATR (14)0.5060 USD
Vol Ratio (20d)1.19x